CANF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Can Fite Biopharma Ltd (CANF) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks clear positive catalysts, recent news, or strong technical signals to support an immediate investment. The financial performance remains weak, with no YoY growth in revenue or earnings, and the analyst downgrade further indicates caution. Holding off for now is recommended.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is in the neutral zone at 72.852, and moving averages are converging, showing no strong directional trend. The stock closed above its pivot point (4.544) but remains below the first resistance level (4.88). Overall, the technical indicators do not strongly support a buy signal.
The MACD is positive and expanding, suggesting some bullish momentum.
The company has weak financial performance with no YoY growth in revenue or earnings, and a recent analyst downgrade to Hold from Buy. Additionally, there are no significant hedge fund or insider trading trends, no recent news, and no congress trading data to support a buy decision.
In Q4 2023, revenue remained flat at $155,000 YoY, net income was -$1,652,000, and EPS was -4.29. There is no sign of financial growth or improvement.
On December 24, 2025, D. Boral Capital analyst Jason Kolbert downgraded the stock to Hold from Buy, citing a reverse split and a corresponding change in the American Depository Share ratio. No price target was provided.
